Sondelbay Dosage/Direction for Use

Posology: The recommended dose of Sondelbay is 20 micrograms administered once daily.
The maximum total duration of treatment with Sondelbay should be 24 months. The 24-month course of Sondelbay should not be repeated over a patient's lifetime.
Patients should receive supplemental calcium and vitamin D supplements if dietary intake is inadequate. Following cessation of Sondelbay therapy, patients may be continued on other osteoporosis therapies.
Special populations: Elderly: Dose adjustment based on age is not required.
Renal impairment: Sondelbay must not be used in patients with severe renal impairment. In patients with moderate renal impairment, Sondelbay should be used with caution. No special caution is required for patients with mild renal impairment.
Hepatic impairment: No data are available in patients with impaired hepatic function. Therefore, Sondelbay should be used with caution.
Paediatric population and young adults with open epiphyses: The safety and efficacy of teriparatide in children and adolescents less than 18 years has not been established. Sondelbay should not be used in paediatric patients (less than 18 years), or young adults with open epiphyses.
Method of administration: Sondelbay should be administered once daily by subcutaneous injection in the thigh or abdomen.
Patients must be trained to use the proper injection techniques. For instructions of the medicinal product before administration (see Special precautions for disposal and other handling under Cautions for Usage). A user manual is also available to instruct patients on the correct use of the pen.